nach oben

PharmacoEconomics

Erschienen in:

01.12.2014 | Current Opinion

“Can We Declare Victory and Move On?” The Case Against Funding Burden-of-Disease Studies

verfasst von: Steven Kymes

Erschienen in: PharmacoEconomics | Ausgabe 12/2014

Einloggen, um Zugang zu erhalten

Abstract

Resources devoted to the development of burden-of-disease studies detract from much needed cost-effectiveness and cost-benefit studies. Practitioners need to help funders of burden-of-disease projects recognize the potential of all tools of decision analysis and economic evaluation in improving the efficiency and equity for the health care system.

Vitale S, Cotch MF, Sperduto R, Ellwein L. Costs of refractive correction of distance vision impairment in the United States, 1999–2002. Ophthalmology. 2006;113(12):2163–70.PubMedCrossRef

Rein DB, Zhang P, Wirth KE, et al. The economic burden of major adult visual disorders in the United States. Arch. Ophthalmol. 2006;124(12):1754–60.PubMedCrossRef

Frick KD, Gower EW, Kempen JH, Wolff JL. Economic impact of visual impairment and blindness in the United States. Arch. Ophthalmol. 2007;125(4):544–50.PubMedCrossRef

Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. 1st ed. New York: Oxford University Press; 1996.

Neumann PJ, Sullivan SD. Economic evaluation in the US: what is the missing link? Pharmacoeconomics. 2006;24(11):1163–8.PubMedCrossRef

AMCP Format Executive Committee. The AMCP Format for Formulary Submissions (Version 3.1). Academy of Managed Care Pharmacy; December 2012.

Patient Protection and Affordable Care Act. 42 USC §18001. vol 111th Congress. 2009–2010.

Gusmano MK. Policy forum: overcoming inequalities: the affordable care act and cancer treatment virtual mentor. Am. Med. Assoc. J. Ethics. 2013;15(8):692–6.

Organization for Economic Cooperation and Development. OECD Health Data 2013. 2013; http://www.compareyourcountry.org/health/health-spending-gdp?cr=oecd&lg=en.

10.

Gray BH, Gusmano MK, Collins SR. AHCPR and the changing politics of health services research. Health Aff. (Millwood). Jan–Jun 2003;Suppl Web Exclusives:W3-283-307.

11.

Lin K. How politically unpopular research from AHRQ helps us make better medical decisions. 2012. http://www.thedoctorweighsin.com/how-politically-unpopular-research-from-ahrq-helps-us-make-better-medical-decisions/. Accessed 12 July 2012.

Titel: “Can We Declare Victory and Move On?” The Case Against Funding Burden-of-Disease Studies
verfasst von: Steven Kymes
Publikationsdatum: 01.12.2014
Verlag: Springer International Publishing
Erschienen in: PharmacoEconomics / Ausgabe 12/2014
Print ISSN: 1170-7690
Elektronische ISSN: 1179-2027
DOI: https://doi.org/10.1007/s40273-014-0200-8

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2014

Rituximab in Combination with Corticosteroids for the Treatment of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: A NICE Single Technology Appraisal

Authors’ Reply to Gandjour: “Are Current Cost-Effectiveness Thresholds for Low- and Middle-Income Countries Useful? Examples from the World of Vaccines”

A Review of the Methodological Challenges in Assessing the Cost Effectiveness of Pharmacist Interventions

A Review of the Economic Burden of Glioblastoma and the Cost Effectiveness of Pharmacologic Treatments

Cost of Illness: An Ongoing Battle Worth Fighting

Acknowledgements